[Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

MLA

Alsuliman, Tamim, et al. “[Medium-Term Follow-up of Patients Treated with Chimeric Antigen Receptor T Cells (CAR T Cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].” Bulletin Du Cancer, vol. 108, no. 12S, Dec. 2021, pp. S65–71. EBSCOhost, https://doi.org/10.1016/j.bulcan.2020.11.015.

APA

Alsuliman, T., Drieu La Rochelle, L., Campidelli, A., Duléry, R., Fayard, A., Mamez, A.-C., Mear, J.-B., Schneider, P. O., Trevet, A., Vicente, C., & Yakoub-Agha, I. (2021). [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bulletin Du Cancer, 108(12S), S65–S71. https://doi.org/10.1016/j.bulcan.2020.11.015

Chicago

Alsuliman, Tamim, Laurianne Drieu La Rochelle, Arnaud Campidelli, Rémy Duléry, Amandine Fayard, Anne-Claire Mamez, Jean-Baptiste Mear, et al. 2021. “[Medium-Term Follow-up of Patients Treated with Chimeric Antigen Receptor T Cells (CAR T Cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].” Bulletin Du Cancer 108 (12S): S65–71. doi:10.1016/j.bulcan.2020.11.015.